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Objectives: This study sought to evaluate the outcome of fresh and vitrified-warmed cleavage-stage and
blastocyst-stage embryo transfers in patients undergoing ART treatment within an ethnic Chinese population.
Study design: We compared the clinical results of embryo transfer on the 3rd (cleavage stage) or 5th (blastocyst
stage) day after oocyte retrieval, including clinical pregnancy rates, implantation rates and multiple pregnancy rates.
Results: Our data showed that blastocyst transfer on day 5 did not significantly increase clinical pregnancy rate
(41.07% vs 47.08%, p>0.05) and implantation rate (31.8% vs 31.2%, p>0.05) in patients under 35 years of age, in
comparison with day 3 cleavage stage embryo transfer. In patients older than 35 years of age, the clinical pregnancy
rate after blastocyst transfer was slightly decreased compared with cleavage stage embryo transfer (33.33% vs
42.31%, p>0.05). Unexpectedly, It was found that vitrified-warmed blastocyst transfer resulted in significantly higher
clinical pregnancy rate (56.8%) and implantation rate (47%) compared with fresh blastocyst transfer in controlled
stimulation cycles (41.07% and 31.8%, respectively). For patients under 35 years of age, the cumulative clinical
pregnancy rate combining fresh and vitrified-warmed blastocyst transfer cycles were significantly higher compared
to just cleavage-stage embryo transfer (70.1% versus 51.8%, p<0.05). However, the cumulative multiple pregnancy
rates showed no significant difference between the two groups.
Conclusions: In an ethnic Chinese patient population, fresh blastocyst transfer does not significantly increase clinical
pregnancy rate. However, subsequent vitrified-warmed blastocyst transfer in a non-controlled ovarian
hyperstimulation cycle dramatically improves clinical outcomes. Therefore, blastocyst culture in tandem with
vitrified-warmed blastocyst transfer is recommended as a favourable and promising protocol in human ART
treatment, particularly for ethnic Chinese patients.
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In a typical ART treatment cycle, fresh cleavage-stage
embryos are routinely transferred [1]. In recent years, with
rapid progress in vitrification technology and blastocyst
culture protocols, transfer of fresh and vitrified-warmed
blastocysts, together with cryopreserved cleavage-stage
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reproduction in any medium, provided the orcommonplace in ART clinical practice [2,3]. Neverthe-
less, the optimal timing for embryo transfer has remained
controversial to date.
A number of studies, as summarized in a Cochrane
review [4], demonstrated the main advantages of blasto-
cyst transfer, including better correlation between mor-
phology and euploidy status and improved implantation
potential due to better synchronization with the endo-
metrium not adversely affected by controlled ovarian
stimulation. These in turn translate to higher pregnancy
and live birth rates after blastocyst transfer, as compared
to cleavage-stage embryo transfer. Nevertheless, conflict-
ing results were reported by a recent Cochrane meta-
analysis, which found no evidence of any difference intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of embryos [5]. Moreover, the same study [5] also found
that blastocyst transfer was associated with an increase in
failure to transfer any embryo in a cycle, as well as a de-
crease in embryo freezing rates. Interestingly, in a recent
study by Langen et al. [6], it was reported that Asian
ART patients (majority of Chinese ethnicity) had signifi-
cantly poorer clinical outcome compared to Caucasians,
even though there was no difference in blastocyst quality
between the two populations. Hence, it is plausible to
hypothesize that endometrial receptivity is more adversely
affected by controlled ovarian stimulation in ethnic
Chinese patients, as compared to Caucasian patients.
Embryo cryopreservation following ART cycles pro-
vided further possibilities of success, in addition to that
achieved with fresh embryo transfer [7]. Therefore cu-
mulative pregnancy rates after completion of both fresh
and additional vitrified embryo transfers per oocyte
retrieval cycle should be considered a more accurate
measure of clinical outcome, rather than just pregnancy
rate per embryo transfer cycle.
Our study retrospectively analyzed the clinical preg-
nancy, implantation and multiple pregnancy rates after
transfer of fresh and vitrified-warmed blastocysts and
cleavage-stage embryos in ethnic Chinese women under-
going ART treatment. The aim is to establish an opti-
mized embryo transfer protocol in clinical ART practice,
at least for ethnic Chinese patients.
Materials and methods
Patients
In order to minimize the influence of various subfertility
factors, only patients younger than 40 years old were
included in this study. From January 2009 to July 2010,
a total of 551 couples including 478 patients younger than
35 years old and 73 patients older than 34 years old were
evaluated retrospectively after the transfer of fresh or
vitrified-warmed embryos at either the cleavage or blasto-
cyst stage. The 478 and 73 patients were allocated to either
cleavage-stage (n=310, <35years and n=52, ≥35, respectively)
or blastocyst-stage (n=168 and 21, respectively) transfer.
The primary outcomes being measured were the cumulative
clinical pregnancy rates and multiple pregnancy rates.
Ovarian stimulation
Standard long protocol for ovarian stimulation was used
for all ART patients, as described previously [8]. Briefly,
this involved down-regulation with GnRH agonist trip-
tolerin (0.1mg S.C. daily until FSH administration, then
reduced to half dose daily) (Decapeptyl, lpsen-biotech,
Paris, France) followed by daily injections with recom-
binant FSH (Serono, Switzerland). Follicular growth was
monitored with ultrasound and measurement of blood
levels of oestradiol, progesterone and LH concentrations.Urinary human chorionic gonadotrophin (HCG: Lizhu,
Zhuhai, China) was administered at a dosage of 5000-
10000 IU(intramuscular) when there were more than two
follicles measuring 18 mm in diameter. Luteal-phase
support with intramuscular injections of progesterone
(60mg daily) was administered on the day of oocyte
retrieval. Transvaginal and ultrasound-guided follicular
aspiration was performed 34-36 h after HCG injection.
The choice of either IVF or ICSI procedure was deter-
mined by semen analysis parameters. IVF and ICSI pro-
cedures were performed as previously described [8].
Blastocyst culture system
Oocyte cumulus complexes were identified, washed in
culture medium (G-IVF; Vitrolife, Gothenburg, Sweden)
under inverted microscope and were cultured in groups
of four or five with 0.9 ml of culture medium per well
inside the tri-gas incubator (Personal MultiGas CO2 in-
cubator, APM-30D, ASTEC, Japan) at 37°C in an environ-
ment of 6% CO2, 5% O2 and 89% N2. The washed oocytes
were then inseminated with either 50,000—100,000 nor-
mal motile spermatozoa (5 hours incubation) or by ICSI
after denudation 2-4 h after pick-up. Subsequently, the
inseminated oocytes were transferred into 50μl drops of
fresh pre-equilibrated culture medium (G1.5; Vitrolife)
under 3.5 ml of sterile paraffin oil (Vitrolife). The follow-
ing day, the oocytes were checked for fertilization status
and then cultured in groups of two to three in fresh
medium under oil for a further 2 days (2- or 8-cell stages).
Scoring of day-3 embryos were performed according to
previously published criteria including cell number, regu-
larity of the blastomeres, fragmentation and morpho-
logical aspects such as granulation [8]. Day-3 embryos
were thus scored on a scale of 1 (high grade) to 4 (low
grade). In the blastocyst transfer group, the embryos were
then regrouped according to their similarity of cell stage
and embryo score and were cultured in groups of two to
three in fresh medium under oil from days 3 to 5. Subse-
quently, the embryos were then transferred to fresh G2.5
medium and cultured for one more day. The blastocysts
were scored according to Gardner’s standard on day 5
and day 6 as described previously [9]. In the cleavage-
stage embryo transfer group, only top-quality embryos
(6- or 8- cell stage with less than 20% fragmentation, and
with symmetrical or very slightly asymmetrical blastomeres)
[8] were either transferred or vitrified on Day3. Culture
of the other non-top-quality embryos was extended for
further 2-3 days until blastocysts were formed. All sur-
plus embryos of good quality on day 3, day 5 or day 6
were cryopreserved through vitrification.
Protocol for vitrification and warming
The cleavage-stage embryos and expanded blastocysts
were vitrified and warmed according to the method
Table 1 Patient characteristics for blastocyst and
cleavage-stage transfer: Jan 2009 ~ Jul 2010















ICSI cycle, no. of patients (%) 90( 29.0) 45(26.8)
Tubal factor, no. of patients (%) 151( 48.7) 83(49.4)
Male factor, no. of patients (%) 43(13.9 ) 23(13.7)
Tubal and male factor,
no. of patients (%)
89( 28.7) 52(31.0)
Multiple factors, no. of patients (%) 27( 8.7) 10(6.0)
Note: Values are presented as number, number (%) or mean ± SD.
ICSI: intracytoplasmic sperm injection.
Duration of infertility, body mass index, percentage of ICSI cycles and
percentage of different infertility factor were all not significantly different
between cleavage-stage and blastocyst transfer group.
a:significant difference between the cleavage-stage and blastocyst transfer
groups (P<0.05) .
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rified by using the commercially-available Cryotop device
and vitrification solutions (Kitazato BioPharma Co.,
Japan). The first equilibration was performed in 7.5%
ethylene glycol (EG) and 7.5% dimethylsulfoxide(DMSO)
at room temperature for 8-10min. Subsequently,
embryos were transferred to 15% EG, 15% DMSO and
0.5 M sucrose for 1 min, and then placed on the film
strip of the Cryotop within a single small drop. The ex-
cess solution was removed to leave just a thin layer
around each embryo and the Cryotop was submerged
into liquid nitrogen, with the strip being covered with a
cap and the sample was stored submerged in liquid nitro-
gen. Upon warming, the cap was removed under liquid
nitrogen and the film strip of Cryotop was quickly sub-
merged for 1 min in 1 ml of 37°C warming solution con-
taining 1.0 M sucrose, followed by transfer of the
embryos to a room temperature solution containing 0.5 M
sucrose, and further incubation for 3 min. After two sub-
sequent wash procedures in basic medium at room
temperature for 10 min in total, the embryos were trans-
ferred into 50μl of culture medium (G2.5; Vitrolife).
Endometrium preparation
A crucial factor for implantation in vitrified-warmed
embryo transfer is exact synchronization between endo-
metrial maturation and embryo development [12].
Vitrified-warmed embryo transfer has been successfully
performed during a natural cycle after spontaneous ovu-
lation [13] or after artificial preparation of the endomet-
rium with exogenous steroids [14]. During artificial
cycles, Estradiol Valerate (Schering, Zydus, Germany)
was administered orally at 3mg twice daily, from Day 2
to Day 7 of the menstrual cycle. After ultrasonography
confirmed an endometrial thickness exceeding 10 mm,
Estradiol Valerate was administered for another 3 more
days and the administration of progesterone (60mg i.m.
daily) was initiated. If the endometrial thickness was <7
mm, Estradiol Valerate dose was increased from 4 mg to
6 mg twice daily in several cases.
Embryo transfer
Patients who have four or more than four top grade
embryos on day 3 (6- or 8- cell stage with less than 20%
fragmentation, and with symmetrical or very slightly
asymmetrical blastomeres) [8] , were selected for blasto-
cyst transfer. Those patients with less than four top grade
embryos on day 3 had cleavage-stage embryo transfer on
day 3. Embryo warming was scheduled on day 3 or day 5
afternoon after the initiation of progesterone adminis-
tration, with vitrified-warmed embryo transfer being
performed on the next day. The time duration from
warming to transfer ranged from 14-16h. Embryo trans-
fer (a maximum of three embryos per transfer) wasperformed under ultrasound guidance. Luteal-phase sup-
port was achieved with intramuscular injections of 60 mg
of progesterone daily for two weeks. Serum hCG concen-
trations were measured 14 days after embryo transfer,
and clinical pregnancy rates per embryo transfer cycle
and implantation rates per transferred embryos were
based on the detection of fetal heart beats by ultrasound,
after 5 weeks following embryo transfer.
Statistical analysis
The results were analyzed statistically by either the
Student’s t-test for comparison of mean values or the
chi-squared test for comparison of percentages using
Statistical Package for Social Science version 13.0 (SPSS,
USA). A value of P<0.05 was considered to be statistically
significant.
Results
A total of 478 couples under 35 years of age were
assigned to either cleavage-stage embryo transfer (n =310
patients) or blastocyst transfer (n =168 patients). There
were no significant differences between the two groups
with respect to patient clinical characteristics except for
age (Table 1). At the same time, a few patients more than
34 years of age were also assigned to undergo embryo
transfer of either cleavage-stage embryos (n=52 patients)
or blastocysts (n=21 patients). Again, patient clinical
characteristics were not statistically different between the
two groups for patients above 34 years of age (Table 2).
Table 2 Patient characteristics for blastocyst and
cleavage-stage transfer: Jan 2009 ~ Jul 2010















ICSI cycles, no. of patients (%) 12(23.1) 5(23.8)
Tubal factor, no. of patients (%) 33(63.5) 10(47.6)
Male factor, no. of patients (%) 4(7.7) 4(19.0)
Tubal and male factor,
no of patients (%)
13(25) 5(23.8)
Multiple factors, no. of patients (%) 2(3.8) 2(9.5)
Note: Values are presented as number, number (%) or mean ± SD.
ICSI: intracytoplasmic sperm injection.
Female patient age, duration of infertility, body mass index, percentage of ICSI
cycles and percentage of different infertility factors were all not significantly
different between the cleavage-stage and blastocyst transfer groups.
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oocytes in the blastocyst transfer group was significantly
higher than the cleavage-stage embryo transfer group
(Table 3, younger than 35 years: 11.43±4.01 versus
7.33±3.57, P<0.05; older than 34 years: 11.24±4.55 versus
6.23±3.68, P<0.05). Additionally, the number of embryos
transferred was significantly different between the two
groups (Table 3) among patients less than 35 years old
(1.75±0.34 versus 2.15±0.55, P<0.05), as well as among
patients aged older than 34 years old (1.76±0.83 versus
2.67±0.76, P<0.05).Table 3 Clinical outcome after fresh blastocyst and cleavage-
Female age < 3
Cleavage-stage
transfer group
No. of patients 274
Retrieved oocytes (mean± SD) 7.33±3.57
No. of embryos transferred (mean± SD) 2.15±0.55
Clinical pregnancy rate, no. (%) 129/274(47.1)
Implantation rate, no. (%) 184/589(31.2)
Multiple pregnancy rate, no. (%) 53/129(41.1)
Singleton pregnancy rate, no. 76
Twin pregnancy rate, no. 51
Triplets pregnancy rate, no. 2
Note : Values are presented as number, number (%) or mean ± SD.
a:significant difference between cleavage stage and blastocyst transfer in two differ
Clinical pregnancy, implantation, and multiple pregnancy rates all show no significa
age groups.For patients under 35 years of age, the clinical preg-
nancy rates (Table 3) in the cleavage-stage embryo trans-
fer group versus blastocyst transfer group were 47.1%
versus 41.7% ( P>0.05) respectively; while the corre-
sponding implantation rates (Table 3) were 31.2% versus
31.8% ( P>0.05) respectively. For patients more than
34 years of age, the clinical pregnancy and implantation
rates after cleavage-stage embryo transfer and blastocyst
transfer (Table 3) also exhibited no significant differences
(42.3% versus 32.3%, P>0.05; 21.6% versus 21.6%, P>0.05,
respectively). The rate of multiple births after cleavage-
stage embryo transfer and blastocyst transfer were 41.1%
versus 40.6% (< 35 years old), and 31.8% versus 14.3%
(> 34 years) respectively, and these were not significantly
different for both groups of patients (Table 3).
The clinical outcomes of the blastocyst and cleavage-
stage embryo transfer groups (under 35 years of age) with
respect to fresh and vitrified-warmed transfer cycles are
shown in Table 4. This data set includes 36 of 310
patients who did not undergo fresh cleavage-stage
embryo transfer due to poor endometrial receptivity on
Day3 (and consequently had all embryos vitrified at the
cleavage stage). Out of 168 patients undergoing fresh
blastocyst transfer in Table 4, 69 patients became preg-
nant (41.7%), leaving behind 99 unsuccessful patients.
Among these 99 patients, 7 patients did not possess any
supernumerary blastocyst for vitrification. Therefore,
only 92 patients had vitrified-warmed blastocyst transfer.
At the same time, out of a total of 310 patients who had
fresh and vitrified-warmed cleavage-stage embryo trans-
fer in Table 4, there were 26 patients who after having
failed to get pregnant upon day 3 transfer, still possessed
supernumerary embryos that formed blastocysts on day
5. These were subsequently vitrified and transferred in
another cycle. Hence, there was a total number of 92 plusstage transfer
















ent age groups (p<0.05).
nt difference between cleavage stage and blastocyst transfer in two different
Table 4 Clinical outcome after vitrified blastocyst and cleavage-stage transfer (age <35 years)
Cleavage-stage transfer Blastocyst Transfer
Fresh group Vitrified group C Fresh group Vitrified group
No. of patients 274 36 168 118
No. of embryos transferred (mean± SD) 2.15±0.55 2.19±0.40 1.82±0.38 1.69±0.58a
Clinical pregnancy rate, no. (%) 129/274 (47.8) 18/36 (50.0) 69/168 (41.7) 67/118 (56.8)b
Implantation rate, no. (%) 184/589 (31.2) 27/79 (34.2) 97/305 (31.8) 94/200 (47.0)b
Mutiple pregnancy rate, no. (%) 53/129 (41.1) 9/18 (50.0) 28/69 (40.6) 26/67 (37.3)
Singleton pregnancy rate, no. 76 9 41 41
Twin pregnancy rate, no. 51 9 27 25
Triplets pregnancy rate, no. 2 0 1 1
Note:values are presented as number, number (%) or mean ± SD.
a:significant difference between cleavage-stage transfer and blastocyst transfer in vitrified group (p<0.01).
b:significant difference between fresh group and vitrified group in blastocyst transfer (p<0.05).
C: patients without transfer in fresh cycles.
Table 5 Cumulative clinical outcome combining fresh and
vitrified-warmed cycles in blastocyst and cleavage-stage





No. of couples 284 194
Overall clinical pregnancies
per couple, no. (%)
147/284(51.8) 136/194(70.1)a
Fresh embryo transfer, no. 129 69
Vitrified-warmed embryo transfer, no. 18 67
Cumulative multiple pregnancy rate,
n (%)
62/147(42.2) 54/136(39.7)
Singleton pregnancy rate, no. 85 82
Twin pregnancy rate, no. 60 52
Triplets pregnancy rate, no. 2 2
Note : Values are presented as number or number (%).
a:significant difference between cleavage-stage transfer and blastocyst transfer
groups (p<0.05).
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transfer in Table 4.
Although different criteria were used in allocating
patients to the vitrified blastocyst and vitrified cleavage-
stage embryo transfer groups, the two data sets in Table 4
are still comparable, because both cases involved non-
controlled ovarian hyperstimulation (non-COH) cycles.
Additionally, it can be presumed that the 118 patients
in the vitrified blastocyst transfer group were previously
unsuccessful due to sub-optimal endometrial receptivity
in their COH cycle, which would mirror the situation in
the vitrified cleavage-stage embryo transfer group.
As seen in Table 4, neither the clinical pregnancy
rate nor implantation rate differed significantly for
cleavage-stage embryo transfer in the fresh versus
vitrified-warmed group (47.8% versus 50.0%; 31.2% ver-
sus 34.2% respectively). In contrast, both clinical preg-
nancy and implantation rates were significantly different
between fresh versus vitrified-warmed blastocyst transfer
cycles (41.7% versus 56.8% and 31.8% versus 47.0%,
respectively, P<0.05). Multiple pregnancy rates were sim-
ilar in both groups among either cleavage-stage embryo
transfer or blastocyst transfer cycles (Table 4).
The cumulative clinical pregnancy rates for fresh and
vitrified-warmed embryo transfers are summarized in
Table 5. Out of 310 patients who had day 3 cleavage-
stage embryo transfer (Table 4), 26 unsuccessful patients
had remaining surplus embryos that were cultured up to
the blastocyst stage and vitrified, prior to being trans-
ferred in a subsequent vitrified-warmed cycle. This would
therefore leave behind a total of 310 – 26 = 284 patients
in the cleavage-stage embryo transfer group of Table 5.
At the same time, 26 patients were added to 168 patients
(Table 4) to give a cumulative total of 194 patients in the
blastocyst transfer group of Table 5. In the blastocyst
transfer group, 67 additional clinical pregnancies were
achieved following vitrified embryo transfers, whereasonly 18 additional clinical pregnancies were achieved in
the cleavage-stage embryo transfer group (Table 5). Hence,
the cumulative clinical pregnancy rate was significantly
higher in patients aged less than 35 years after blastocyst
transfer, as compared to patients with cleavage-stage
embryo transfers (70.1% versus 51.8%, p<0.05). There
was however no significant difference in the cumulative
multiple pregnancy rates of both groups.Discussion
The ultimate aim of an ART procedure is to achieve one
singleton live birth per stimulated cycle. However, it is
still unclear which embryo transfer model will achieve
optimal results for ART patients. To try to resolve this
question, 551 couples were assigned to fresh or vitrified-
warmed embryo transfer at either the cleavage stage or
blastocyst stage for their first or second ART attempt.
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an anticipated enhancement of implantation rate with
blastocyst transfer, we limited the number of embryos
transferred per cycle to three or less. Therefore, a max-
imum of three embryos were placed in each cryotop dur-
ing vitrification. This is reflected in significantly lesser
number of embryos being transferred in the blastocyst
transfer group compared to the cleavage-stage transfer
group. Hence, a trend towards lower multiple pregnancy
rates was therefore observed in blastocyst transfer cycles.
Nonetheless, there was no significant difference between
the two groups with respect to implantation rate. Mean-
while our retrospective meta-analysis showed that the
transfer of fresh blastocysts on day5 did not significantly
increase clinical pregnancy rate and implantation rate
within the general ART patient population compared
with day3 cleavage-stage embryo transfer. In fact, the
rates for blastocyst transfer were slightly decreased com-
pared with cleavage-stage transfer, particularly in patients
aged older than 34 years.
These findings are consistent with another recent study
[15], which also reported that blastocyst culture and
transfer reduced implantation and pregnancy rates in the
general ART patient population compared to cleavage-
stage embryo transfer. Nevertheless, positive results of
blastocyst transfer have been reported by many previous
studies, which all revealed higher implantation and
pregnancy rates with blastocyst transfer compared to
cleavage-stage embryo transfer [16-20]. It is difficult to
explain why the results of our study demonstrated neg-
ligible advantages of blastocyst transfer, despite com-
parable baseline clinical characteristics, other than the
patient age being significantly younger and the number
of oocytes retrieved being significantly higher in the
blastocyst transfer group. Nevertheless, while all of the
above differences should be considered advantageous,
being good prognostic factors for both blastocyst forma-
tion and pregnancy [21], this potential advantage did not
translate into higher implantation and pregnancy rates
for the blastocyst transfer group in this study. Several
studies have underlined the difficulties of correctly
selecting the best embryo on Day 2-3 [22,23]. The aim of
extending embryo culture to Day 5/6 was to select an
embryo with increased probability of implantation rather
than just to improve embryo quality [19]. Another recent
meta-analysis [24] suggested that the putative clinical
superiority of blastocyst transfer protocols needs to be
further verified and that the cumulative clinical preg-
nancy rate combining both fresh and cryopreserved
embryo transfer cycles would be the more reliable mea-
surable outcome for comparison.
In this study, it was surprisingly observed that vitrified-
warmed blastocyst transfer for patients aged less than
35 years resulted in significantly higher clinical pregnancyand implantation rates compared with fresh blastocyst
transfer. Our results are consistent with a previous study
that reported significantly higher ongoing pregnancy, cli-
nical pregnancy, and implantation rates in cryopreserved
versus fresh embryo transfer cycles [25]. Differences in
implantation rates between the two groups may reflect
different endometrial receptivity and a higher degree of
synchronization between endometrial development and
the transferred blastocysts in vitrified-warmed cycles [26].
Our overall results demonstrated that in women under-
going their first or second ART attempt with vitrified-
warmed embryo transfers, the cumulative clinical pregnancy
rate was significantly increased upon blastocyst transfer,
as compared to the transfer of cleavage-stage embryos. It
is suggested that if embryo-endometrium synchrony was
suboptimal, the embryos should be cryopreserved for a
subsequent transfer under more optimal conditions [27].
Therefore, the concept of cryopreserving all available
embryos and transferring them in subsequent non-
stimulated cycles may enhance embryo-endometrium
synchrony and clinical outcomes of ART cycles in some
patients. This in turn may provide a number of clinical
benefits, including increasing the cumulative pregnancy
rates, reducing the risk of OHSS and decreasing patient
discomfort and cost without the need for superovulation.
Although a trend towards lower cumulative multiple
pregnancy rate was also noticed in blastocyst transfer
cycles, this still needs to be further improved and dimin-
ished to a minimum by modifying the embryo transfer
strategy.
The results of this study therefore demonstrate that
blastocyst culture and transfer is not suited for all
ART patients. This could be because later embryonic
development to the blastocyst stage and beyond is also
dependent on maternally transcribed mRNA stored
within the oocyte [28]; and we hypothesize that some
patient with poorer quality oocytes (i.e. older women)
may have abnormally low levels of such stored mRNA
transcripts, leading to arrest of blastocyst formation.
Examples of maternally transcribed mRNA that play im-
portant roles in blastocyst formation and beyond include
CDX2 involved in trophectoderm function and mainten-
ance of the blastocoelic cavity [29], and STK40 impli-
cated in extra-embryonic endoderm differentiation [30].
Hence, blastocyst culture and transfer should be
offered primarily to younger patients (less than 35 years)
with better prognosis, in tandem with blastocyst vitrifica-
tion. Undoubtedly, blastocyst transfer will still remain a
favourable and promising option in ART. In future, the
efficacy of embryo transfer at the blastocyst stage could be
fully optimized through further refinement and improve-
ment of current blastocyst cryopreservation protocols.
In any case, the ultimate aim of reproductive medi-
cine practitioners would still be the improvement of ART
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optimal outcome in current ART practice is the delivery
of singleton infants rather than multiple births. To this
end, blastocyst culture in tandem with blastocyst vitrifi-
cation and single-blastocyst transfer emerges as a highly
efficient protocol in human ART treatment.
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